Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Subscribe To Our Newsletter & Stay Updated
